Travere Therapeutics Inc

We are aware that some stockholders voiced their dissatisfaction with the number of boards that Mr. Orwin served on last year by withholding votes for his re-election last year. At the time of our last annual meeting, Mr. Orwin was continuing to serve as the President and CEO of Atreca, Inc., though Atreca had entered into an asset purchase agreement for the sale of Atreca’s antibody-related assets and materials to Immunome, Inc., which closed in May 2024. Following the closing of that transaction, Mr. Orwin no longer serves as an executive officer of a public company. Mr. Orwin currently serves on two other public company boards, as the Chair of the Board of Directors of CARGO Therapeutics, Inc. and as the Chair of the Board of Directors for AnaptysBio, Inc. Our Corporate Governance Guidelines limit the total number of public company boards a director may serve on to no more than four boards in addition to ours, which is consistent with the current policy of the proxy advisory firm Institutional Shareholder Services (“ISS”). For any Board member who is a named executive officer at another public company, our Corporate Governance Guidelines limit the number of public company boards they may serve on to two boards in addition to ours, which is also consistent with current ISS policy. All of our directors are in compliance with our policy regarding the number of public company boards they may serve on.